JonesResearch analyst Soumit Roy keeps a Buy rating on CytomX Therapeutics (CTMX) with a $7 price target after the company announced the new drug application submission with the FDA seeking accelerated approval for dordaviprone in the recurrent H3K27M diffuse glioma setting. If Chimerix receives priority review, an FDA action date will be set as early as Q3 of 2025, the analyst tells investors in a research note. Additionally, the firm expects topline interim survival data in Q3 from the Phase 3 trial in 1L H3K27M mutated glioma. 2025 is “shaping up to be a major catalyst year” for Chimerix, contends Jones.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- Biotech Alert: Searches spiking for these stocks today
- CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler
- CytomX Therapeutics Reports Q3 Progress and Growth
- CytomX Therapeutics reports Q3 EPS 7c, consensus (17c)
- CTMX Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
